HEALEY ALS Platform Trial — Multi-Arm Adaptive Trial at Mass General
The HEALEY ALS Platform Trial changed how ALS drug development works. Instead of running one drug in one trial at a time — each requiring its own placebo arm, its own site activation, its own protocol review — the platform model tests multiple experimental treatments simultaneously against a single shared placebo arm. Treatments rotate in and out as evidence accumulates. The infrastructure stays in place even as individual regimens complete. This cuts time, reduces the number of patients assigned to placebo, and allows the field to test more drugs per year than the traditional single-drug model ever could.
What the platform model is and why it matters
A platform trial is a single master protocol that allows multiple treatment regimens to be evaluated simultaneously within one trial framework. All participants share common eligibility criteria, common baseline assessments, and a common data infrastructure. Participants are randomized to one of the active treatment regimens or to a shared placebo group. When a regimen completes its evaluation — showing either sufficient signal to advance or insufficient signal to continue — it exits the platform, and a new regimen can enter without requiring the entire trial apparatus to be rebuilt from scratch.
For ALS, a disease affecting roughly 30,000 Americans at any given time with dozens of candidate therapies seeking evaluation, the platform model is not just more efficient — it may be the only realistic way to evaluate the full pipeline in meaningful timeframes. A rare disease population can only sustain so many parallel single-drug trials before site and patient capacity constraints create bottlenecks. Pooling infrastructure into a shared platform eases those constraints.
The HEALEY trial is run by the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital and is supported by the ALS Association, the Prize4Life Foundation, and multiple pharmaceutical sponsors who pay to enter the platform with their candidate therapy.
What regimens have been tested
The HEALEY platform has evaluated multiple treatment regimens since its launch. Each regimen involves a specific drug and duration, randomized within the master protocol.
Pridopidine was one regimen evaluated in the HEALEY platform. The primary endpoint in the overall HEALEY pridopidine arm was not met — pridopidine did not show significant slowing of progression in the full enrolled population. However, a subgroup analysis in 284 participants with early, rapidly progressive ALS showed 32% slowing of ALSFRS-R decline at 24 weeks (P = 0.03), along with 62% reduction in respiratory function worsening and 88% slowing of dyspnea decline. These subgroup results provided the basis for FDA clearance of the dedicated Phase 3 PREVAiLS trial in the target population. The 120 HEALEY pridopidine participants were compared to 164 participants in the shared placebo group.
Other regimens tested in the HEALEY platform have included: AMX0035 (combination of sodium phenylbutyrate and taurursodiol — later FDA-approved as Relyvrio before subsequent market withdrawal); and additional investigational agents at various stages. The platform is ongoing, with new regimens continuing to enter.
Why the platform design is important for rare disease research
Traditional ALS drug development has a poor track record partly because most trials are underpowered, too short, use heterogeneous populations, and lack the infrastructure to detect modest but real treatment effects. The platform model addresses several of these problems at once.
The shared placebo arm is perhaps the most impactful element. Historically, roughly 30% of ALS trial participants were assigned to placebo — contributing nothing to the specific drug's evaluation but still consuming enrollment capacity and trial resources. In a platform with multiple active treatment arms, the ratio of active-to-placebo participants improves, meaning more patients contribute useful efficacy data relative to the total enrolled. For a disease where patients are acutely aware that trial participation may be their only access to experimental treatments, this matters ethically as well as practically.
The HEALEY model has also demonstrated that a functioning trial infrastructure — trained sites, established protocols, regulatory agreements — can test multiple drugs within a single framework and then sustain itself over years. Other rare disease fields are now looking at the HEALEY model as a template for their own pipeline challenges.
PLS relevance
PLS patients are not enrolled in the HEALEY platform trial, which has ALS-specific eligibility criteria. The platform design concept is, however, highly relevant to the future of PLS drug development. The PLS Natural History Study is building the outcome measure and biomarker infrastructure that would allow a PLS platform trial to function. If and when a PLS platform trial is established, the HEALEY model provides a practical template for how it could work — evaluating multiple candidate agents against a shared natural history comparator in a rare disease population that cannot sustain dozens of separate parallel trials.
How this connects
The HEALEY trial produced the HEALEY-arm subgroup data that justified the PREVAiLS Phase 3 pridopidine trial — so the two pages are closely linked. For a broader view of the ALS drug trial landscape and what it means for PLS patients, see Drug Trial Research. For information on finding and participating in trials currently enrolling, including the PLS Natural History Study, see Clinical Trials.
Citation
HEALEY ALS Platform Trial. ClinicalTrials.gov NCT04297683. Massachusetts General Hospital / Sean M. Healey and AMG Center for ALS. Phase 2/3 adaptive master protocol platform trial. Ongoing.